Indivior (NASDAQ:INDV) Shares Down 9.2%

Indivior PLC (NASDAQ:INDV) traded down 9.2% during trading on Thursday . The company traded as low as $16.11 and last traded at $16.17. 1,305 shares traded hands during trading, a decline of 87% from the average session volume of 10,028 shares. The stock had previously closed at $17.80.

Indivior Price Performance

The company has a 50-day simple moving average of $20.13. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.98 and a quick ratio of 0.99. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -9.66 and a beta of 0.42.

Institutional Trading of Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN bought a new stake in shares of Indivior in the second quarter worth $34,000. Qube Research & Technologies Ltd bought a new stake in Indivior during the third quarter valued at $41,000. Mackenzie Financial Corp increased its stake in Indivior by 0.3% during the third quarter. Mackenzie Financial Corp now owns 562,595 shares of the company’s stock valued at $12,979,000 after purchasing an additional 1,909 shares during the last quarter. Renaissance Group LLC increased its stake in Indivior by 2.1% during the third quarter. Renaissance Group LLC now owns 97,127 shares of the company’s stock valued at $2,241,000 after purchasing an additional 1,959 shares during the last quarter. Finally, Swiss National Bank increased its stake in Indivior by 1.0% during the third quarter. Swiss National Bank now owns 287,897 shares of the company’s stock valued at $6,257,000 after purchasing an additional 2,727 shares during the last quarter. Institutional investors own 36.26% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia.